SEC Tracker
Get the app

Caribou Biosciences CRBU

Caribou Biosciences to restructure operations

Form
8-K
Filed
Importance
Notable
  1. Restructuring includes discontinuing clinical trials for vispa-cel and CB-011
  2. Estimated costs of $15M-$19M for restructuring
  3. Workforce reduction expected in Q4 2026
  4. Cash, cash equivalents, and marketable securities of $113.8M as of June 30, 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Caribou Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Protara Therapeutics PRTO public float $112M, Jun 30, 2025
  2. Fate Therapeutics FATE public float $113M, Jun 30, 2025
  3. Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
  4. TuHURA Biosciences HURA public float $111M, Jun 30, 2025
  5. Enanta Pharmaceuticals ENTA public float $111M, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.